References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2013-10-11-15

medsovet-1116

Research Article

ЗАБОЛЕВАНИЯ ВЕРХНИХ ОТДЕЛОВ ЖКТ

DISEASES OF THE UPPER GASTROINTESTINAL TRACT

Клинико-молекулярные аспекты резистентности Helicobacter pylori к антибактериальным препаратам

Сlinical and molecular aspects of helicobacter pylori resistance to antimicrobial drugs

Кучерявый

Ю. А.

Kucheryaviy

Y. A.

noemail@neicon.ru

Андреев

Д. Н.

Andreyev

D. M.

noemail@neicon.ru

Баркалова

Е. В.

Barkalova

E. V.

noemail@neicon.ru

ГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава РоссииРоссияMoscow State University of Medicine and Dentistry named after A.I. Evdokimov, Russian Ministry of HealthRussian Federation

2013

30122013

0101115

2013

Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В.

Kucheryaviy Y.A., Andreyev D.M., Barkalova E.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/1116

В обзоре литературы представлены современные представления о клинических и молекулярных аспектах антибиотикорезистентности Helicobacter pylori (H. pylori). На сегодняшний день рост количества штаммов H. pylori резистентных к основным препаратам, используемым в схемах терапии первой линии, рассматривается как главная причина неудач лечения инфекции. В общемировой популяции показатели распространенности резистентных штаммов H. pylori варьируют в различных географических зонах в широких пределах, коррелируя с общей частотой применения антибиотиков в популяции. Текущие мировые консенсусные рекомендации регламентируют дифференцированную стратегию выбора схем эрадикационной терапии в зависимости от уровня резистентности H. pylori к кларитромицину, что объясняется высокой клинической значимостью данного варианта устойчивости.

The literature review tells about current views on the clinical and molecular aspects of antibiotic resistance of Helicobacter pylori (H. pylori). Today, the growing number of H. pylori strains resistant to the first-line regimens is considered to be the main reason of treatment failure. In the total global population, incidence of drug-resistant strains of H. pylori varies greatly across different geographic areas and correlates with the total frequency of antibiotics intake by the corresponding population. Latest global consensus recommendations regulate a differential choice strategy in selecting eradication therapy. The choice should take into account the level of resistance of H. pylori to clarithromycin, as this type of resistance has greatest clinical significance.

Helicobacter pyloriэрадикацияантибиотикорезистентностькларитромицинметронидазоламоксициллинтетрациклинлевофлоксацинрифабутинфуразолидонHelicobacter pylorieradicationmetronidazoleamoxicillintetracyclinelevofloxacinrifabutinfurazolidone

References1

De Francesco V., Ierardi E., Hassan C., Zullo A. Helicobacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther. 2012; 3(4):68-73.

Castro-Fernández M., Vargas-Romero J. Infection with Helicobacter pylori. Prevalence, research and impact of antibiotic resistance. Rev Esp Enferm Dig. 2009; 101(11):743-56.

Georgopoulos S.D., Papastergiou V., Karatapanis S. Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: A paradigm shift to improved efficacy. Gastroenterol Res Pract. 2012; 2012: 757926.

Wu W., Yang Y., Sun G. Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol Res Pract. 2012; 2012:723183.

Francesco V.D., Zullo A., Hassan C., et al. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol. 2011;2(3):35-41.

Iwańczak F., Iwańczak B. Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance. Adv Clin Exp Med. 2012;21(5):671-80.

Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374–1384.

Gerrits M.M. Molecular mechanisms of antibiotic resistance in Helicobacter pylori. Erasmus MC, Netherlands, 2004: chap 2: 17-46.

De Francesco V., Giorgio F., Hassan C., et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010; 19(4): 409-14.

Megraud F. Antimicrobial Resistance and Approaches to Treatment. In: Sutton P, Mitchell H, M., editors. Helicobacter pylori in the 21st Century. Wallingford, UK: CABI; 2010.

Perez Aldana L., Kato M., Nakagawa S., et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7: 306-309.

Elviss N.C., Owen R.J., Breathnach A., et al. Helicobacter pylori antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnic diverse populations in central and south London during 2000. J Med Microbiol 2005; 4: 567-74.

Glupczynski Y., Megraud F., Lopez-Brea M., et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-3.

Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34-42.

Исаева Г.Ш. Резистентность H. pylori к антибактериальным препаратам и методы ее определения. Клин. микробиол. и антимикроб. химиотер. 2010; 1:57-66.

Барышникова Н.В., Денисова Е.В., Корниенко Е.А. и др. Эпидемиологическое исследование резистентности Helicobacter pylori к кларитромицину у жителей Санкт-Петербурга с язвенной болезнью. Экспер и клин гастроэнтерол 2009; 5:73—76.

Осипенко М.Ф., Бикбулатова Е.А., Шакалите Ю.Д., Чернова Л.Н. Резистентность Helicobacter pylori к кларитромицину в Новосибирске. Рос журн гастроэнтерол, гепатол, колопроктол 2012; 5 (Приложение 40): 36.

Перфилова К.М., Неумоина Н.В., Неумоина М.В. и др. Изучение резистентности H. pylori к макролидам у больных с хроническими заболеваниями желудка и двенадцатиперстной кишки. Рос журн гастроэнтерол, гепатол, колопроктол 2012;5 (Приложение 40): 37.

Лазебник Л.Б., Рустамов М.Н. Резистентность к кларитромицину при эрадикации HP у больных дуоденальной язвой. Тез. докл. XII съезда Научного общества гастроэнтерологов России «Классическая и прикладная гастроэнтерология» 1—2 марта 2012 г. М: 20.

Malfertheiner P., Megraud F., O’Morain C. et al; European Helicobacter Study Group. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut 2012; 61 (7): 646-664.

Маев И.В., Самсонов А.А., Андреев Д.Н. и др. Современные аспекты диагностики и лечения инфекции Helicobacter pylori (по материалам консенсуса Маастрихт IV, Флоренция, 2010). Мед. совет 2012; 8: 10-19.

Fischbach L., Evans E.L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26(3):343-57.

De Francesco V., Margiotta M., Zullo A., et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Inter Med 2006; 144: 94-100.

Rimbara E., Noguchi N., Kawai T., Sasatsu M. Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. Antimicrob Agents Chemother. 2008;52:3465–3466.

Kim J.M., Kim J.S., Kim N., et al. Gene mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pylori strains isolated from Korean patients. J Microbiol Biotechnol. 2008;18:1584–1589.

Hirata K., Suzuki H., Nishizawa T., et al. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J Gastroenterol Hepatol. 2010;25 Suppl 1:S75–S79.

Paulsen I.T. Multidrug efflux pumps and resistance: regulation and evolution. Curr Opin Microbiol. 2003;6:446–451.

Zhang Z., Liu Z.Q., Zheng P.Y., et al. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol. 2010;16:1279–1284.

Кудрявцева Л.В. Состояние антибиотикорезистентности Helicobacter pylori в России. Эксп. клин. гастроэнтерол. 2003; 3: 4–5.

Цуканов В.В., Штыгашева О.В., Баркалов С.В. Эпидемиология язвенной болезни (монография). Красноярск: Сибирь 2004; 198.

Цуканов В.В., Амельчугова О.С., Буторин Н.Н., и др. Современные аспекты эрадикации Helicobacter pylori. Тер архив 2013; 2: 73–75.

Marais A., Bilardi C., Cantet F., et al. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res Microbiol. 2003;154(2):137-44.

Moore J.M., Salama N.R. Mutational analysis of metronidazole resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2005;49:1236–1237.

Smith M.A., Edwards D.I. Oxygen scavenging, NADH oxidase and metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother. 1997;39:347–353.

Guerrits M.M., van Vliet A.H.M., Kuipers E., et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006; 6: 699-709.

Gerrits M.M., Godoy A.P., Kuipers E.J., et al. Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori. Helicobacter. 2006;11(3):181-7.

Rimbara E., Noguchi N., Kawai T., Sasatsu M. Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori. J Antimicrob Chemother. 2008;61:995–998.

Co E.M., Schiller N.L. Resistance mechanisms in an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother. 2006;50:4174–4176.

Nonaka L., Connell S.R., Taylor D.E. 16S rRNA mutations that confer tetracycline resistance in Helicobacter pylori decrease drug binding in Escherichia coli ribosomes. J Bacteriol. 2005; 187(11):3708-12.

Wu J.Y., Kim J.J., Reddy R., et al. Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob Agents Chemother. 2005;49:578–583.

Trieber C.A., Burkhardt N., Nierhaus K.H., Taylor DE. Ribosomal protection from tetracycline mediated by Tet(O): Tet(O) interaction with ribosomes is GTP-dependent. Biol Chem. 1998;379:847–855.

Perna F., Zullo A., Ricci C., et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007;39(11):1001-5.

Nishizawa T., Suzuki H., Nakagawa I., et al. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2008; 23 (Suppl. 2):S167-70.

Bogaerts P., Berhin C., Nizet H., Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter. 2006;11:441–445.

Fujimura S., Kato S., Iinuma K., Watanabe A. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol. 2004;53:1019–1022.

Tankovic J., Lascols C., Sculo Q., et al. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2003;47(12):3942-4.

Glocker E., Bogdan C., Kist M. Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany. J Antimicrob Chemother 2007; 59: 874-879.

Chisholm S.A., Teare E.L., Davies K., et al. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005). Euro Surveill 2007;12: E3-4.

Nishizawa T., Suzuki H., Matsuzaki J., et al. Helicobacter pylori resistance to rifabutin in the last 7 years. Antimicrob Agents Chemother. 2011;55(11):5374-5.

Heep M.S., Odenbreit D., Beck J., et al. Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins. Antimicrob. Agents Chemother. 2000, 44:1713-5.

Su Z., Xu H., Zhang C., et al. Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance. Croat Med J. 2006;47(3):410-5.

Abadi A.T., Taghvaei T., Mobarez A.M., et al. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol. 2011;49(6):987-93.

The authors declare that there are no conflicts of interest present.